Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With NDD-CKD
Status:
Unknown status
Trial end date:
2021-05-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and efficacy of
Pegol-Sihematide, as compared with recombinant human erythropoietin injection (CHO Cell),
ESPO, in anemia treatment in patients with non-dialysis-dependent chronic kidney disease.